Over the last few months, PDCI Market Access Inc., Connex Health and H3 Consulting have undertaken an initiative to better understand the Canadian private payer product listing agreement (PLA) landscape and how it has evolved ... Read More
At PDCI Market Access Inc., our vision at PDCI is to be your most trusted and valued pricing and reimbursement strategic partner. To ensure we continue to meet the strategic needs of our customers in the face of the ever-changing Canadian reimbursement landscape, we’ve expanded our Health Economic ... Read More
PDCI Market Access is
pleased to release our premier issue of PDCI
Market Access INSIGHTS online journal to
our Market Access Toolkit subscribers. The articles in our first issue provide
deep dives into:
Planning and budgeting PSPs during the pandemic,New data and new perspectives on private insurers and ... Read More
PDCI is pleased to announce the release of the 2020 update to the PDCI Census of Insurers. The PDCI Census of Insurers is available exclusively through the PDCI Market Access Toolkit. PDCI’s Census of Insurers estimates the market share and private covered lives by insurer across ... Read More
In June 2020, PMPRB launched a public consultation on its new draft Guidelines as a next step towards implementing the recently amended Patented Medicines Regulations. The deadline to submit written feedback is today,August 4, 2020. Details on submitting a consultation response can be found on the PMPRB ... Read More
ALERT! PMPRB WEBINAR RESCHEDULED
Given all the new information this week, as well as the consultation extension, PDCI is postponing its PMPRB webinar. Our second free webinar for industry will now be held on July 22, 2020 between 10:30 am – 12:00 ... Read More
CADTH’s Pharmaceutical Reviews Updates are used to communicate new Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH ... Read More
As PDCI announced earlier today, the PMPRB has issued the second draft of the PMPRB Guidelines to support the implementation of Patented Medicines Regulations (Regulations) changes coming unto force on January 1, 2021. This draft is now available for a 30-day Notice and Comment Period. Written feedback ... Read More
The Patented Medicine Prices Review Board (PMPRB) has just released its second set of Draft Guidelines under the recently amended Patented Medicines Regulations (“Regulations”). This launches a 30-day consultation period for stakeholders to provide written comments on the new Draft Guidelines.
Stay ... Read More
